UroGen Pharma Ltd.
URGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $172 | $95 | $55 | $44 |
| Short-Term Investments | $65 | $42 | $45 | $45 |
| Receivables | $20 | $15 | $13 | $12 |
| Inventory | $9 | $6 | $4 | $5 |
| Other Curr. Assets | $10 | $11 | $12 | $9 |
| Total Curr. Assets | $276 | $169 | $129 | $114 |
| Property Plant & Equip (Net) | $4 | $2 | $4 | $3 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $5 | $5 | $0 | $1 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $2 | $3 | $2 |
| Total NC Assets | $10 | $9 | $7 | $5 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $286 | $178 | $136 | $120 |
| Liabilities | – | – | – | – |
| Payables | $11 | $7 | $6 | $6 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $35 | $25 | $18 | $17 |
| Total Curr. Liab. | $46 | $31 | $24 | $22 |
| LT Debt | $123 | $99 | $99 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $3 | $3 |
| Other NC Liab. | $125 | $113 | $99 | $86 |
| Total NC Liab. | $249 | $212 | $201 | $89 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $1 | $2 | $0 |
| Total Liabilities | $295 | $244 | $225 | $111 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$806 | -$679 | -$577 | -$467 |
| AOCI | $0 | $0 | -$0 | -$0 |
| Other Equity | $797 | $614 | $488 | $476 |
| Total Equity | -$9 | -$65 | -$89 | $8 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $286 | $178 | $136 | $120 |
| Net Debt | -$49 | $4 | $44 | -$44 |